CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
The prognostic significance of serum TGF-?1 levels in patients with Crimean-Congo hemorrhagic fever
Authors
M. Arslan
S.C. Karahan
+5 more
U. Kostakoğlu
İ. Köksal
A. Menteşe
G. Yilmaz
H. Yilmaz
Publication date
1 January 2017
Publisher
'Wiley'
Doi
Cite
Abstract
PubMed: 27467498Crimean-Congo Hemorrhagic Fever (CCHF) may exhibit a mild clinical course or a severe profile like mortal bleeding. The pathogenesis of the illness and reason of bleeding are unclear. However, endothelial injury is a key factor in the pathogenesis of the illness. Transforming growth factor beta (TGF-?) is one of the materials involved in repairing injured endothelium. This is a significant polypeptide released in pretty much all cells and important for the regulation of cellular events, epithelium formation, inflammation, blood coagulation, and collagen synthesis. This study aimed to determine the prognostic significance of serum TGF-?1 levels in CCHF patients. We examined 120 patients hospitalized with CCHF diagnosis and their serum TGF-?1 was investigated, retrospectively. Patients were put into two groups according to the existence of hemorrhage. Forty-four (36.7%) patients had hemorrhage. TGF-?1 levels in patients with bleeding were 5.2 ± 1.8, and 7.1 ± 2.2 for non-bleeding (P < 0.0001). When ROC analysis was performed in patients with CCHF alone in order to identify patients with bleeding, at a TGF-?1 cut-off point of 4.9, AUC was 0.762 (0.675–0.835), sensitivity 59.1%, specificity 85.5%, PPV 70.3%, and NPV 78.3%. We summarize that TGF-?1 level and endothelial dysfunction can be related. A decreased TGF-?1 level is a likely prognostic and diagnostic factor for bleeding in CCHF patients. Therefore, this marker should be considered in the treatment strategy for these patients. J. Med. Virol. 89:413–416, 2017. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc
Similar works
Full text
Available Versions
DSpace @ Recep Tayyip Erdoğan Üniversitesi Akademik Açık Arşiv
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:acikerisim.erdogan.edu.tr:...
Last time updated on 27/02/2021